Business Context and Reporting Period
Company: Prothena Corporation plc (PRTA)
Filing Type: Form 8-K (Current Report)
Date of Report: July 30, 2021
Event: Entry into a Material Definitive Agreement with Bristol Myers Squibb (BMS).
Key Financial Metrics
This filing reports a specific transaction rather than periodic financial performance. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity for the reporting period.
- Upfront Payment Received: $80 million from BMS.
- Potential Milestones (U.S. License): Up to $465 million.
- Potential Milestones (Global Option): Up to $562.5 million (if global rights are exercised).
- Royalties: Tiered royalties ranging from high single-digit to high-teen percentages on net sales.
Material Changes
On July 30, 2021, Prothena entered into a U.S. License Agreement with BMS, exercising an option under their existing Master Collaboration Agreement. Key changes include:
- Exclusive U.S. License: BMS secured exclusive rights to develop, manufacture, and commercialize antibody products targeting Tau (PRX005) in the United States.
- Immediate Cash Inflow: Prothena received an $80 million upfront payment.
- Future Optionality: BMS retains the option to exercise global rights for PRX005 following Phase 1 clinical study results, which would trigger an additional $55 million fee and increase total potential milestones to $562.5 million.
- Remaining Portfolio Options: BMS holds options for TDP-43 and an undisclosed target with aggregate potential exercise fees of up to $270 million and milestones up to $1.125 billion.
Guidance, Outlook, and Risks
Management Commentary and Outlook: Prothena is currently running the Phase 1 clinical study for PRX005. The future financial impact depends on the achievement of regulatory approvals, sales thresholds, and BMS's decision to exercise global rights.
Risks and Contingencies:
- Termination Rights: Either party may terminate for material breach, bankruptcy, or safety reasons. Prothena may terminate for failure of due diligence or patent challenges by BMS.
- Payment Reductions: Exercise fees, milestones, and royalties are subject to certain reductions as specified in the agreement.
- Dependency: Future milestone payments are contingent on developmental events and commercial success by BMS.
Investor Verification Checklist
- Verify the receipt of the $80 million upfront payment in upcoming cash flow statements.
- Monitor the results of the Phase 1 clinical study for PRX005 to assess the likelihood of BMS exercising the global rights option ($55 million fee).
- Review the full text of the Tau U.S. License Agreement (to be filed as an exhibit to the Q3 2021 10-Q) for specific reduction clauses and royalty tier details.
- Track the status of BMS's options for the TDP-43 and undisclosed target programs.